LumiCyte Signs Distribution Agreement with Shimadzu Corp., Expanding Global Reach to Japan.Business Editors/Health & Medical Writers BIOWIRE2K FREMONT, Calif.--(BW HealthWire)--June 24, 2002 LumiCyte, Inc. -- Five-Year Agreement Grants Shimadzu Exclusive Marketing and Distribution Rights to Sell LumiCyte's Proprietary SELDI-based Protein-Mapping Services, and Includes a Multi-Million Dollar Investment by Shimadzu in LumiCyte LumiCyte, Inc., a biotechnology services innovator, today announced that it has signed an exclusive agreement for Kyoto, Japan-based Shimadzu Corp. to market and distribute LumiCyte's proprietary SELDI-based protein mapping services in Japan. The 5-year agreement with Shimadzu, valued at more than $30 M USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. , is the first expansion of LumiCyte's distribution capability outside of the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . Beyond the distribution of LumiCyte's services, the agreement includes a multi-million dollar investment by Shimadzu. Founded in 1875, the Shimadzu Corporation is a $1.6 billion company (FY2001) that provides a wide range of highly value-added products and systems, including measuring instruments, medical, aircraft and industrial equipment. Shimadzu will commit a team to market and sell LumiCyte's proprietary SELDI-based protein discovery and biomarker validation services -- in the form of milestone-based contracts - to pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. in Japan to help them optimize their drug development efforts. "Shimadzu's decision to invest in LumiCyte after an extensive evaluation process reflects our view that we have a winning strategy and business model for Japan. We believe their distinguished history and leadership in clinical proteomics and bioinformatics will enable our customers in Japan to rapidly implement the best solutions available for drug development," said Mr. Shigehiko Hattori, managing director, marketing and sales for Shimadzu. "Our investment in LumiCyte represents an important strategic decision for Shimadzu. LumiCyte is using the most powerful biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of platform technology for protein mapping and discovery we know, providing biomarker information with speed, accuracy and depth that is unmatched by competitive offerings." "Shimadzu's excellent reputation and relations with big pharmaceutical, biotechnology and medical institutions in Japan will help accelerate LumiCyte's introduction of our advanced technologies to this important market," said Dr. T. William Hutchens, LumiCyte founder, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and inventor of SELDI SELDI Surface Enhanced Laser Desorption/Ionization technology. LumiCyte's services are based on its advanced SELDI biochips, its powerful data analysis tools and its BioPhore Knowledgebase(TM), which includes LumiCyte's large human serum protein database. LumiCyte uses these proprietary technologies to rapidly measure disease-related protein profiles from only trace amounts of blood. Unlike other biochip approaches, LumiCyte's proprietary SELDI-based protein mapping technology does not require specific biomarker proteins to be known in advance, nor does it require the generation of specific capture agents, or labeling to detect the proteins. This greatly simplifies and accelerates the biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. and validation process. Invented by LumiCyte's CEO, Dr. T. William Hutchens, during his tenure at the Baylor College of Medicine Baylor College of Medicine is a private medical school located in Houston, Texas, USA on the grounds of the Texas Medical Center. It has been consistently rated the top medical school in Texas and among the best in the United States. at the Texas Medical Center in Houston, SELDI has been hailed by many experts for its fundamental utility in the field of proteomics and has aided and enabled breakthrough discoveries in disease research. LumiCyte holds exclusive rights to use the SELDI technology to sell SELDI-based discovery services and information to the life sciences industry. LumiCyte also holds exclusive rights to provide diagnostic instruments and devices, protein biochip consumables, services, information and other products for use by individuals. The multi-million dollar investment by Shimadzu adds to funding that LumiCyte has received from Redleaf Venture Management, Tullis-Dickerson & Co., Inc., and OrbiMed Advisors LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . About Shimadzu Corp. Shimadzu Corporation, the world leading company for the analytical instruments manufacturing, consists of four major divisions including analytical & measuring instruments, medical systems, aircraft equipment, and semiconductor equipment, with $1.6 billion of consolidated net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight for fiscal 2001 approximately. The headquarters is based in Kyoto, Japan with 8,000 employees worldwide. Targeting the life science market as one of its major focused areas, it offers the comprehensive range of genomic and proteomic products including High throughput DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. /protein sequencers and reagents for prompt direct PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) . DNA /protein analysis services are available as well. http://www.shimadzu.com/ About LumiCyte, Inc. The advanced, proprietary biotechnology services offered by Fremont, CA-based LumiCyte, Inc. allow pharmaceutical and biotechnology companies to optimize drug development and enable physicians to offer more individualized in·di·vid·u·al·ize tr.v. in·di·vid·u·al·ized, in·di·vid·u·al·iz·ing, in·di·vid·u·al·iz·es 1. To give individuality to. 2. To consider or treat individually; particularize. 3. and accurate care to their patients. http://www.lumicyte.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion